FDA Accepts ZTlido NDA for Postherpetic Neuralgia
Scilex Pharmaceuticals announced that the Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for ZTlido (lidocaine patch 1.8%) for the treatment of postherpetic neuralgia (PHN), or after-shingles pain.
Scilex filed the NDA for ZTlido during the third quarter of 2015. In addition to the progress with ZTlido, Scilex is expanding its product suite for the treatment of pain with the development of several other products.
ZTlido is a fourth-generation branded lidocaine patch formulation.
For more information call (610) 644–5352 or visit ScilexPharma.com.